CGEM Cullinan Oncology Inc

Price (delayed)

$17.63

Market cap

$1.08B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.37

Enterprise value

$1.01B

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build ...

Highlights
The debt is up by 30% year-on-year but it has declined by 11% since the previous quarter
Cullinan Oncology's equity has decreased by 34% YoY and by 10% from the previous quarter
CGEM's net income is down by 24% YoY

Key stats

What are the main financial stats of CGEM

CGEM stock price

How has the Cullinan Oncology stock price performed over time
Intraday
2.03%
1 week
-4.6%
1 month
14.93%
1 year
127.19%
YTD
70.34%
QTD
-3.19%

Financial performance

How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$240.35M
Net income
-$221.04M
Gross margin
N/A
Net margin
N/A
CGEM's net income is down by 24% YoY
The operating income has contracted by 15% YoY

Price vs fundamentals

How does CGEM's price correlate with its fundamentals

Growth

What is Cullinan Oncology's growth rate over time

Valuation

What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
2.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 21% year-on-year
The price to book (P/B) is 143% higher than the 5-year quarterly average of 1.2 and 108% higher than the last 4 quarters average of 1.4
Cullinan Oncology's equity has decreased by 34% YoY and by 10% from the previous quarter

Efficiency

How efficient is Cullinan Oncology business performance
CGEM's return on invested capital has dropped by 84% year-on-year and by 14% since the previous quarter
Cullinan Oncology's return on equity has shrunk by 74% YoY and by 12% QoQ
The company's return on assets has shrunk by 69% YoY and by 10% QoQ

Dividends

What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CGEM.

Financial health

How did Cullinan Oncology financials performed over time
The total liabilities has increased by 32% year-on-year but it has declined by 7% since the previous quarter
CGEM's total assets is down by 30% year-on-year and by 10% since the previous quarter
The debt is 99% smaller than the equity
Cullinan Oncology's equity has decreased by 34% YoY and by 10% from the previous quarter
The debt is up by 30% year-on-year but it has declined by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.